OraSure Technologies, which develops and manufactures oral fluid diagnostic devices, is expanding into the molecular diagnostics market with its $53 million cash acquisition of DNA Genotek. OraSure says that the deal will provide it with a complementary portfolio of products that enable collection, stabilization, transportation, and storage of high-quality DNA and RNA samples. “Our companies share a common capability and passion to develop best-in-class oral fluid-based solutions. Since 2004, DNA Genotek has posted impressive financial revenue growth and profitability, and we fully expect that solid performance to continue," stated Douglas A. Michels, OraSure's president and CEO.
